Cardiovascular and pulmonary adverse events associated with BCMA-directed chimeric antigen receptor T-cell therapy
Authors:
- Zhiqiang SongZSZhiqiang Song
- Zhendong FuZFZhendong Fu
- Yuyan ChenYCYuyan Chen
- Dongliang ZhangDZDongliang Zhang
- Yuke GengYGYuke Geng
- Jie WangJWJie Wang
- Na LiuNLNa Liu
- Gusheng TangGTGusheng Tang
- Jianmin YangJianmin Yang
Open Access
- 1 October 2026
- journal article
- Published by KEAI Publishing in Genes & Diseases
Abstract
No abstract availableFunding Information
- National Natural Science Foundation of China
- Science and Technology Commission of Shanghai Municipality
This publication has 5 references indexed in Scilit:
- Cardiovascular complications and their association with short‐ and long‐term outcomes in patients with multiple myeloma undergoing chimeric antigen receptor T‐cell therapyBritish Journal of Haematology, 2025
- Cardiovascular adverse events and outcomes after anti-BCMA CAR-T for relapsed and refractory multiple myelomaBlood Cancer Journal, 2025
- Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myelomaBlood Advances, 2023
- Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label studyThe Lancet, 2021
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple MyelomaNew England Journal of Medicine, 2021